Norethindrone Stopped Working: How to Troubleshoot a Plateau or Non-Response

What a Norethindrone Plateau Actually Means

A plateau is not the same as a failed drug. Norethindrone acetate reduces menstrual blood loss by thinning the endometrium and suppressing prostaglandin-driven uterine contractility. When that effect diminishes, the problem is almost always one of three things: the dose no longer matches your physiology, a structural or hormonal condition is working against the drug, or adherence has drifted in ways that are easy to underestimate.

The 2013 Cochrane-cited systematic review of progestins for heavy menstrual bleeding found that norethindrone acetate at 5 mg twice daily significantly reduced menstrual blood loss compared with placebo, but the authors noted substantial variability in response, pointing to patient-level factors rather than a drug that simply stops working over time.

Before changing your prescription, a structured audit of the five commonest plateau drivers saves you from unnecessary switches.

The Five Most Common Plateau Drivers

1. Dose erosion over time. Endometrial tissue can become relatively less sensitive to a fixed progestin dose, especially if body weight has increased or if perimenopausal estrogen fluctuations are rising.
2. Missed or mistimed doses. Even one or two missed doses per week can blunt the atrophic effect on endometrium enough to restore bleeding.
3. An unaddressed structural lesion. Submucosal fibroids, endometrial polyps, and adenomyosis all cause bleeding that is largely progestin-resistant.
4. A newly developed or worsening comorbidity. Hypothyroidism, coagulopathy (especially von Willebrand disease), and uncontrolled PCOS each drive bleeding independent of progestin effect.
5. Drug-drug interaction reducing bioavailability. Enzyme inducers including rifampin, phenytoin, and carbamazepine can lower norethindrone plasma levels by 50% or more.

Life-Stage Differences That Change the Whole Picture

Your hormonal environment at each life stage determines how well norethindrone performs. One dose does not fit all ages.

Reproductive Years (Ages 18-40)

In regularly cycling women, norethindrone acetate works against a backdrop of cyclical estrogen that rebuilds endometrium every month. ACOG Practice Bulletin No. 128 on heavy menstrual bleeding recommends excluding structural causes (PALM components) before attributing non-response to the drug itself. Women with PCOS are a particular subgroup: anovulatory cycles create unopposed estrogen, meaning the endometrium may be significantly thicker at baseline, requiring higher or longer progestin courses to achieve adequate atrophy.

Trying to Conceive

Norethindrone is not compatible with active conception attempts. It suppresses ovulation at higher doses and alters cervical mucus at the mini-pill dose of 0.35 mg. If you are trying to conceive, norethindrone should be stopped and an alternative investigated for cycle control or endometriosis management.

Perimenopause (Typically Ages 40-51)

This is where plateau is most frequently misattributed. Perimenopausal estrogen surges can be dramatic. A dose of 5 mg norethindrone acetate that controlled bleeding at 42 may be overwhelmed by the erratic estrogen spikes that appear at 47. The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement acknowledges that progestin requirements in perimenopause are often higher than in the stable postmenopausal state because of fluctuating endogenous estrogen. Dose escalation or a switch to a higher-efficacy progestin delivery route (levonorgestrel IUD) is frequently the correct answer here.

Postmenopause

In women using norethindrone as the progestin component of combined hormone therapy after menopause, breakthrough bleeding after a period of stability should trigger endometrial evaluation, not automatic dose escalation. ACOG Committee Opinion 556 notes that any unscheduled postmenopausal bleeding warrants ruling out endometrial pathology first.

Pharmacokinetics: Why Women Metabolize Norethindrone Differently

Norethindrone acetate is completely converted to norethindrone after oral absorption. Peak plasma concentration (Cmax) is reached in approximately 1-2 hours, with a half-life of 8-11 hours. That short half-life matters clinically: a single missed evening dose in a twice-daily regimen can reduce 24-hour exposure by nearly half.

Sex-specific pharmacokinetic differences are real but incompletely characterized. Body fat percentage influences the volume of distribution for progestins; women with higher adiposity may show lower free norethindrone concentrations at a given dose because of sequestration in adipose tissue. A pharmacokinetic analysis published in the Journal of Clinical Pharmacology confirmed that norethindrone area under the curve (AUC) varies up to 3-fold between individuals, even with identical dosing, which explains why one woman thrives at 5 mg while another needs 10 mg for equivalent endometrial suppression.

The WomanRx Norethindrone Plateau Audit Framework:

| Step | Clinical Question | Action if Positive | |---|---|---| | 1 | Is adherence truly consistent? | Pill diary for 4 weeks before any dose change | | 2 | Any new enzyme-inducing drug? | Check interaction database; consider dose increase or alternative | | 3 | Weight change >10% since starting? | Recheck dose by weight-adjusted norethindrone PK | | 4 | Pelvic imaging in past 12 months? | Order saline infusion sonohysterography or pelvic MRI | | 5 | Thyroid, CBC, coagulation panel done? | Order if not done in past year | | 6 | Life stage shift (perimenopause onset)? | Consider LNG-IUD or dose escalation with estrogen add-back data |

Structural Causes That Mimic Progestin Non-Response

Submucosal fibroids and adenomyosis are the two conditions most likely to produce a treatment response that looks like a plateau. Both are progestin-resistant in significant ways.

Submucosal Fibroids

Type 0 and Type 1 submucosal fibroids distort the uterine cavity and generate mechanical bleeding that no oral progestin dose will fully control. A 2017 study in Obstetrics & Gynecology found that women with any submucosal component to their fibroids had significantly higher menstrual blood loss scores than women with intramural-only disease, regardless of medical therapy. Hysteroscopic myomectomy, not a higher norethindrone dose, is the correct intervention.

Adenomyosis

Adenomyosis is often invisible on standard transvaginal ultrasound and requires MRI or experienced sonographer review to detect. The ectopic endometrial glands embedded in the myometrium respond poorly to systemic progestins because drug penetration into myometrial tissue is limited. In women with confirmed adenomyosis and norethindrone plateau, a levonorgestrel-releasing IUD delivers progestin directly to the uterine cavity at concentrations 100-1,000 times higher than oral dosing, and is supported by ACOG's guidance on adenomyosis management.

Endometrial Polyps

Polyps are frequently missed on standard ultrasound. Saline infusion sonohysterography has a sensitivity of approximately 88-95% for intracavitary lesions per a meta-analysis in Fertility and Sterility. Any woman with norethindrone plateau who has not had cavity evaluation in the past year should have this done before the dose is escalated.

Hormonal and Metabolic Conditions That Block Response

PCOS and Anovulatory Bleeding

Women with PCOS have chronically elevated estrogen relative to progesterone, producing a proliferative endometrium that requires higher progestin doses and longer duration of exposure to thin adequately. The 2018 International PCOS Guidelines recommend that anovulatory women on progestin therapy be assessed for metabolic comorbidities including insulin resistance, since hyperinsulinemia amplifies androgen and estrogen production and may reduce apparent progestin efficacy.

Thyroid Disease

Hypothyroidism increases menstrual blood loss through multiple mechanisms: impaired platelet function, reduced clotting factor synthesis, and anovulation. A study in the Journal of Clinical Endocrinology & Metabolism found that women with subclinical hypothyroidism (TSH 4-10 mIU/L) had meaningfully heavier periods than euthyroid controls. If you are on norethindrone for heavy bleeding and your last TSH was more than 12 months ago, get it rechecked. Treating the thyroid often reduces bleeding independently.

Von Willebrand Disease and Coagulopathy

Up to 20% of women with heavy menstrual bleeding have an underlying coagulation disorder, with von Willebrand disease being the most common per CDC estimates. Progestins do not correct coagulopathy. A woman who has never had a bleeding disorder workup and is labeled a norethindrone non-responder deserves screening with VWF antigen, VWF activity, and factor VIII before any further dose escalation.

Dose Escalation: What the Evidence Supports

For heavy menstrual bleeding, the dose range studied in clinical trials is 5 mg twice daily to 5 mg three times daily for days 5-26 of the menstrual cycle, or continuously at lower doses. The Cochrane progestins review found that cyclical norethindrone at 5 mg twice daily reduced menstrual blood loss by approximately 87% in one included trial, compared with a 97% reduction with the levonorgestrel IUD in the same review, which establishes the ceiling for what oral norethindrone can realistically achieve.

For endometriosis, norethindrone acetate at 5 mg/day, titrated to 10 mg/day if needed, is supported by ACOG Practice Bulletin 114. Doses above 10 mg/day are outside the label and carry higher risk of irregular bleeding, mood changes, and androgenic side effects.

Side Effects That Increase With Dose Escalation

Higher doses of norethindrone acetate carry:

• Androgenic effects (acne, hair thinning) due to norethindrone's partial androgenic activity
• Mood changes and depression, particularly in women with a prior history of hormonal mood sensitivity
• Lipid changes: norethindrone acetate reduces HDL and may raise LDL at doses above 5 mg/day. A pharmacodynamic review in Contraception showed dose-dependent HDL suppression with norethindrone-containing regimens
• Bone density: long-term high-dose norethindrone without adequate estrogen may reduce bone mineral density, relevant in women over 40 or those with baseline osteopenia

When to Switch Away From Norethindrone

Some non-responses are genuine indications to change strategy entirely. Consider switching when:

• Two adequate dose escalations (with documented adherence) have failed to reduce bleeding by at least 50%
• Structural pathology is confirmed and surgical management is indicated
• Side effects at therapeutic doses are intolerable
• The woman is perimenopausal and would benefit more from a combined estrogen-progestin or LNG-IUD approach
• Endometriosis has progressed despite medical therapy and laparoscopic evaluation is warranted

Alternatives with supporting evidence:

| Alternative | Best for | Key trial | |---|---|---| | Levonorgestrel IUD (Mirena) | HMB, adenomyosis | NEJM ECLIPSE trial | | Tranexamic acid | Non-hormonal option for HMB | ACOG HMB Bulletin | | GnRH agonist + add-back | Endometriosis, fibroids | Lupron NDA studies, FDA label | | Combined OCP | PCOS, endometriosis | ACOG PCOS Practice Bulletin |

Pregnancy, Lactation, and Contraception: Required Reading

Norethindrone is contraindicated in confirmed pregnancy. This is not a relative caution. Animal studies and human case series have raised concern for virilization of a female fetus when progestins with androgenic activity are used in the first trimester per the FDA prescribing information for norethindrone acetate. If pregnancy is confirmed while you are taking norethindrone, stop the drug and contact your clinician the same day.

Contraception Requirement

Women of reproductive age using norethindrone acetate at doses above the mini-pill dose (0.35 mg) for indications such as endometriosis or heavy menstrual bleeding should use reliable non-hormonal or barrier contraception unless the dose and timing are already providing reliable contraceptive suppression. Higher doses do suppress ovulation, but the contraceptive reliability of off-label dosing regimens has not been studied in the same rigor as the 0.35 mg mini-pill.

Lactation

The 0.35 mg norethindrone mini-pill is one of the preferred contraceptive options during lactation because progestin-only methods do not suppress milk supply the way combined estrogen-progestin pills can. CDC Medical Eligibility Criteria for Contraceptive Use (US MEC) classifies progestin-only pills as Category 1 (no restriction) for women who are at least 6 weeks postpartum and breastfeeding. Norethindrone does transfer into breast milk in small amounts; no adverse effects in nursing infants have been documented at the 0.35 mg dose, but data at higher therapeutic doses used for HMB or endometriosis are limited. Women using 5-10 mg/day for non-contraceptive indications while breastfeeding should discuss the risk-benefit balance with their clinician.

Postpartum Timing

Progestin-only pills can generally be started at 6 weeks postpartum in breastfeeding women. In non-breastfeeding postpartum women, they can be started earlier. Postpartum heavy bleeding that does not resolve by 12 weeks warrants evaluation for retained products, uterine subinvolution, or postpartum thyroiditis before starting norethindrone.

Who This Is Right For, and Who It Is Not

Good Candidates for Continued or Escalated Norethindrone

• Women with HMB and a structurally normal uterus on cavity evaluation
• Women with endometriosis seeking non-surgical management
• Perimenopausal women with anovulatory heavy bleeding and no contraindication to progestins
• Women with PCOS who need endometrial protection from unopposed estrogen
• Women seeking progestin-only contraception during lactation

Poor Candidates or Cases Needing Rethink

• Women with confirmed submucosal fibroids requiring surgical correction
• Women with documented coagulopathy (progestins will not fix the underlying defect)
• Women with active or past breast cancer (progestins are generally avoided; discuss with oncologist)
• Women with severe depression or history of progestin-induced mood disorder at therapeutic doses
• Women with uncontrolled hepatic disease (norethindrone is hepatically metabolized and is contraindicated in significant liver impairment)
• Pregnant women (contraindicated)

Monitoring While on Norethindrone

A plateau audit is not a one-time event. Women on norethindrone for longer than 6 months deserve a structured review annually. The minimum set:

• Menstrual blood loss assessment (pictorial blood assessment chart or validated tool such as the PBAC score)
• Blood pressure check (progestins can have modest effects on BP at higher doses)
• Lipid panel if dose is 5 mg/day or higher
• TSH if not checked in past 12 months
• Pelvic imaging if symptoms have changed or worsened
• Bone density (DXA) if on high-dose norethindrone for more than 2 years without adequate estrogen exposure, especially in women over 45

ACOG Practice Bulletin 136 on management of abnormal uterine bleeding recommends reassessing response to medical management at 3-6 months and again at 12 months, not waiting indefinitely before changing strategy.